Talaris Therapeutics

Cell Processing Facility & Corporate Office
570 S. Preston St.
Louisville, KY 40202
United States

Email: info@talaristx.com

NextGen Class of 2020
Show jobs for this employer

About Talaris Therapeutics

Talaris Therapeutics is developing a breakthrough, one-time cell therapy to enable patients who receive a living donor kidney transplant to no longer require lifelong immunosuppression, without rejecting their donated organ. 

Achieving durable, drug-free immune tolerance to a donated organ has been referred to as a “Holy Grail” of organ transplant.  In a ground-breaking, phase 2 study conducted between 2008 - 2016, our lead therapy, FCR001, enabled 70% of patients to be weaned off all immunosuppression within 12 months of their kidney transplant. No tolerized patient has had to resume immunosuppression.  We have followed these patients for an average of almost five years since their transplant, and the longest for over ten years.  Our single-dose cell therapy has also shown the potential to induce durable remission of certain types of severe auto-immune diseases, and to benefit other solid organ transplant patients.  Talaris has announced a $100M private financing from leading life sciences investors and has initiated a Phase 3 pivotal trial of our therapy in living donor kidney transplant patients.  We also expect to initiate two Phase 2 trials of our therapy in additional indications in 2020.  Our cell processing facility and most of our operations are based in Louisville, KY, and we also have a corporate office in Boston, MA.

7 articles with Talaris Therapeutics